Corporate Presentation October New growth cycle and value innovation

Size: px
Start display at page:

Download "Corporate Presentation October New growth cycle and value innovation"

Transcription

1 Corporate Presentation October 2017 New growth cycle and value innovation

2 Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational Performance 5 Capital Markets 2

3 Dental benefits: an incipient sector in Brazil 3 1

4 Brazil leads the global ranking of dentists Number of dentists per country (thousand) 290 ¹ 12% of the dentists in the world are located in Brazil Source: FDI World Dental Federation The Oral Health Atlas 2009 ¹ Federal Council of Dentistry Brazil (September 2017)

5 Brazilian dental opportunity Although 12% of world s dentists are located in the country, only 11% of brazilians have a dental plan 60% 11% % of the population covered by a private dental plan 14 5 Source: OdontoPrev

6 Great portion of middle class don t have dental plan Potential Market of 78 Million people in the middle class Million people already dental plan members million people 6

7 Proprietary research confirms importance of dentistry Do you believe your smile is your best business card? 76% totally/partially agree 7 Totally disagree Partially disagree Neutral Partially agree Totally agree

8 Cost per client Cost per client Attractive cost dynamics Over time, OdontoPrev Dental Plans present a predictable Medical Plans OdontoPrev Plans Price Cost Price Cost Time Cost increases by medical inflation and better technology Short-term contract: 1 year tenor TIme Predictable cost evolution due to prevention Long-term contract: 2 year + duration 8 and more attractive cost profile than Medical Plans.

9 OdontoPrev Prepaid Business Model High predictability of cash flow No working capital needs Low CAPEX requirements Positive cash flow generation every day Customers Fee per user Dental care reimbursement R$ R$ Accredited dentist network 9

10 Inside OdontoPrev2

11 OdontoPrev: 10 years of sustainable value creation since IPO Net revenues (R$ million) 1,070 1,156 1,250 1,365 1, IPO JUL16 JUN17 11

12 Revenue & membership market share: Revenue market Share (%) Membership market Share (%) ¹ Source: ANS and OdontoPrev ¹ OdontoPrev membership portfolio ex-bradesco

13 Individual plans & SME: higher growth and better returns JUL16 - JUN17 AVERAGE TICKET (R$ / member / month) Contribution Margin 37 Individual Plans Revenues JUL16-JUN17 R$273 M (+33% YoY) 53% 20 Corporate SME Revenues JUL16-JUN17 R$202 M (+16% YoY) 43% 17 Revenues JUL16-JUN17 R$918 M (-2% YoY) 38% 13 ¹ M: million High Low NUMBER OF COMPETITORS

14 Strategic competitive advantages 3

15 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 15

16 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 16

17 Proprietary IT Platform: information-driven decisions 17 + Complete dental record of all beneficiaries + 29 years of actuarial data + Risk Management and fraud prevention

18 Proprietary IT Platform: information-driven decisions + Quality assurance + Clear barrier to entry + Cost control 18

19 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 19

20 Increasing online search for dental plans Number of dental plans search in Brazil (000 / month) 20

21 Innovation driven Company + OdontoPrev online: individual plans sold at the web + Launched NEW September 1st + Exclusive App for the accredited dentists network 21

22 Wide range of unique dental care solutions OdontoPrev online Baby tooth Well being Dental Aesthetics Dental Orto Dental VIP 22

23 From basic cover to aesthetic solutions Fluorine Pediatric dentistry 24/7 emergency Surgery Wisdom tooth extraction Restoration Cleanings Orthodontic radiography Braces Whitening Prosthesis Baby tooth Well being Being Dental Dental aesthetics Dental Orto Dental VIP 23

24 Innovation driven Company Top quality dental materials delivered door to door to the dentist free of charge Exclusive agreement to prevent oral cancer 24

25 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 25

26 Dental and medical plans evolution Million members Medical plans Dental plans AUG/ AUG/17 26 Source: ANS August 2017.

27 Dental Plans sector evolution Million members AUG17 27 Source: ANS

28 Focused & dental only leadership since 1998 Key players, brazilian dental sector (AUGUST 2017 thousand members) 6,190¹ 27% market share of beneficiaries² 1,943 1,640 1, ¹OdontoPrev 2Q17 ² Source: ANS ( ) ( )

29 3 accelerated growth cycles, over the last decade, brings new investors to the sector

30 Cycle 01: Bradesco Dental (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) % 23.3% 23.9% % Source: ANS

31 Cycle 02: Amil sold to UnitedHealthcare in 2013 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) % 24.9% 23.8% 25.5% Source: ANS

32 Negative results in Brazil Net loss (R$ million) Source: Amil (Valor Econômico)

33 Cycle 03: Hapvida & Interodonto 2014 JUL17 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) % 26.2% 22.0% 23.3% JUL16 JUN Aug/ Aug/17 33 Source: ANS

34 Dental plans sector evolution DEC14 AUG17 Thousand members ,667 20, Others DEC14 With 18% of market share, three companies represented 68% of the sector growth since AUG17 34 Source: ANS

35 Change in control brings a new strategy of peers Thousand members ( ) 1,878 2,062 1,808 1,846 1,944 1,943 1,571 1,260 1,262 1, ,011 1,054 ( ) AUG/17 35 Source: ANS

36 Cross-selling dental/medical has limited upside Players Dental (A) Medical (B) A / B % % 36 Source: ANS August 2017

37 Average ticket evolution (R$/member/month) N/A Source: ANS

38 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 38

39 Best in class distribution channels Direct selling Bank channels Brokers Online selling Retailers Medical Plan Organizations 39

40 The largest bancassurance platforms in Brazil Clients + 80 million + 60 million National footprint Exclusivity 20 years 48% of branches & 52% of brazilian bank clients 40

41 Banks: strong and committed long-term partners + Back-office Price maker Product design Customer relationship Dentist network management Front-office Price takers Selling National footprint capilarity Bank branches and brokers distribution 41

42 Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 42

43 Largest and best dentist network 28,000 dentists at 2,200 cities National distribution Differentiated academic background Continuous education 24/7 call center 43

44 OdontoPrev: 4 Financial and Operational Performance

45 More positive headlines 45

46 Net Revenues R$ million 1,402 1,156 1,250 1, , % % JUL16 6M16 6M17 2Q16 2Q17 JUN17

47 Revenue growth per segment in 2Q17 R$ million R$ million +20.6% +4.6% % % 69% 14% 65% 20% 15% Q16 2Q17 2Q16 2Q17 Corporate SME Individual Plans 47

48 2Q17 Members, revenues and contribution margin Members Revenue Contribution Margin 75% 15% 10% 65% 20% 15% 61% 23% 16% Corporate SME Individual Plans 48

49 Average Ticket per Segment (R$/member/month and YoY % ) +12.6% 2.1% % Q16 2Q17 2Q16 2Q17 2Q16 2Q17 Corporate SME Individual Plans 49

50 Breakdown of individual plans Thousand members +4% % 657 3% 2% 56% 41% 258K members 43% 283K members 55% 2Q16 2Q17 Retailers 50

51 Positive effects of bank channels 2Q17 List prices & R$45.60 Retailers R$29.90 Selling expenses Profitability 10% - 15% Higher 25% - 45% Lower 51

52 Breakdown of SME members Thousand members +6% % 83% 16% 79% 7% 14% 718K members 721K members 2Q16 2Q17 52

53 Quarterly and LTM Cost of Services (% of Sales) Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q¹ Quarterly LTM 53 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

54 Dental Loss Ratio (% of Sales) per segment Corporate SME Individual Plans 2Q16 3Q16 4Q16 1Q17 2Q17 54

55 Key metrics per segment (% of Sales) Q16 2Q17 2Q16 2Q172Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 Corporate SME Individual Plans Cost of Services Selling expenses Contribution Margin 55

56 G&A (% of Sales) Personnel Others # of employees 1,525 1,587 1,560 1,588 1,581 1,460 1, M17¹ 56 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

57 Allowance for doubtful receivables R$ million and % of Sales Q16 3Q16 4Q16 1Q17 2Q17 R$ million % of Sales 57 57

58 Adjusted EBITDA and Adjusted EBITDA margin (ex-inss¹) R$ million and % of Sales JUL16 6M16 6M17¹ 2Q16 2Q17¹ JUN17¹ 58 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

59 Net Income (ex-inss¹) R$ million JUL16 JUN17¹ 6M16 6M17¹ 2Q16 2Q17¹ 59 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

60 Quarterly cash dividends to investors (R$ million) INSS approval brings 100% payout policy from 3Q Q16 2Q16 3Q16 4Q16 1Q17 2Q17 Dividends Interest on capital 60

61 Net cash (R$ million) 515¹ 443¹ Q17 61 ¹ Includes R$114.8 million dedicated to ANS.

62 Cash Flow since the IPO R$ million +2, % of sales Share buyback Capital reductions -1,428.9 Cash dividends , Net Cash DEC = Cash Generation Acquisitions Capex Shareholder Remuneration Stock Options² Net Cash JUN17¹ 62 ¹ Includes R$114.8 million dedicated to ANS ² Stock Options Program vesting reimbursement

63 INSS: Provisions reversals in 2Q17 Until 2010 After 2010 Amount provisioned R$45 million R$303 million Approval July 10th, 2017 July 14th, 2017 Cash effect Yes, in 3Q17 No Annual growth Selic (*) Selic (*) + R$ 45 million 63 * Brazilian interest rate

64 Key takeaways More positive outlook for new members Loss ratio back to historical levels Tax savings to expand margin From 80% to 100% payout ratio 64

65 Capital Markets 5

66 Global shareholder structure: investors from 37 countries 66 Source: OdontoPrev

67 Corporate Governance and professional management team 67

68 Superior Corporate Governance Standards Chairman # CEO, since the 1990s Board of Directors without executive functions, 56% independent members AGM previous notice to shareholders of 30 days Disclosure of minimum, average and maximum annual compensation of executives 3 CEOs since the foundation in 1987, and 1 IRO since IPO 68

69 Key Metrics for management s compensation Quantitative goals Perception Studies Revenue EBITDA (R$) Number of members Beneficiaries Dentists HR managers Quality of services 69

70 OdontoPrev awarded for the 8th consecutive year... Best Healthcare Sector IR Team of Latin America 2010 / 2011 / 2012 / 2013 / 2014 / 2015 / 2016 / Thank you! 70

71 Feedback from the street Well-run company, experienced and focused management team, complying with high Corporate Governance standards. Leadership position in a defensive market with favorable growth prospects. Strong balance sheet and cash generative business. One of the world s best emerging markets business models We continue to view OdontoPrev as the best business model in the healthcare segment, combining a high return and cash-flow-generation profile. #1 Company in Latin America with a technological competitive advantage Strong fundamentals stand out on current environment. We believe that high multiples are supported by: 1) strong FCF generation; 2) balance sheet with no debt; 3) dividend yield and 4) high earnings visibility. 71

72 Upcoming IR events Date Country Broker Event Oct 3, 2017 Oct 12, 2017 Oct 13, 2017 Oct 25, 2017 Oct 26, 2017 Oct 26, 2017 Nov 1, 2017 Nov 13, 2017 Nov 14-15, 2017 Nov 16-17, 2017 NDR Bradesco - Santiago NDR HSBC - Johannesburg NDR HSBC - Cape Town 3Q17 Earnings Release 3Q17 Webcast Investor Presentation - São Paulo NDR Credit Suisse - Rio de Janeiro ESG NDR UBS - New York Bradesco 7th Annual CEO Forum - New York ESG NDR HSBC - London Nov 20-21, 2017 Itaú BBA's 10th LatAm Conference - London Nov 30, 2017 JP Morgan 10th Brazil Opportunities Conference - São Paulo Jan 10-12, 2018 Jan 30-31, 2018 Morgan Stanley 10th Annual LatAm Executive Conference - Miami Credit Suisse LatAm Investment Conference - São Paulo 72 OdontoPrev s Investor Relations activities, including conference calls, webcasts, one-on-one meetings and public presentations are made by the Company s CEO and/or IRO since the 2006 IPO.

73 Why OdontoPrev? Largest and best network of dental specialists Proven & sustainable business model State-of-the-art IT platform Superior corporate governance standards Solid capital structure Proven management with an incentive to drive shareholder value Multiple growth drivers High returns on capital 73

74 Your award winning Investor Relations Team José Roberto Pacheco Executive Director & IRO Roberta Carneiro IR Manager Phone: + 55 (11) ir@odontoprev.com.br : OdontoPrevIR Darcio Nunciatelli IR Analyst Corporate Headquarters Avenida Marcos Penteado de Ulhôa Rodrigues 939 Torre II / Edifício Jatobá / 14 th floor Barueri. São Paulo. Brazil Stella Hong IR Analyst Custodian & Market Maker Independent Auditors B3 Ticker 74

Corporate Presentation 1Q18. New growth cycle and value innovation

Corporate Presentation 1Q18. New growth cycle and value innovation Corporate Presentation 1Q18 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Sustainability 4 Strategic competitive advantages 5 Financial

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market. September 28th, 2012

Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market. September 28th, 2012 Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market September 28th, 2012 All rights reserved 2012 Disclaimer This presentation may contain forward-looking statements.

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

MARCH 2014 RESULTS PRESENTATION Madrid, 2014 MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted

More information

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset

More information

Prodent Introduction. Welcome

Prodent Introduction. Welcome Prodent Introduction Welcome 1 MEET PRODENT Over 25 years of operation in the market Over 600,000 members Over 1,700 corporate clients Over 17,000 care options Exclusive dental focus Centralized capital

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor

More information

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company

More information

The Dental Corporation Opportunity

The Dental Corporation Opportunity The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,

More information

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1- BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

LED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF

LED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF LED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF WHAT WE DO LED Medical Diagnostics Inc. provides software and imaging device solutions to Dentists, Dental Support Organizations (DSOs) & the US Military

More information

Endesa 1Q 2017 Results 09/05/2017

Endesa 1Q 2017 Results 09/05/2017 Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

Total Face Group Limited

Total Face Group Limited Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position

More information

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports

More information

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday

More information

To be the partner of choice Straumann

To be the partner of choice Straumann To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities

More information

ASX Investor Presentation

ASX Investor Presentation ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Letter to Shareholders SEMI-ANNUAL REPORT 2008 Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

Altria Group Inc. Ticker: MO

Altria Group Inc. Ticker: MO Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

ASX Announcement 22 June 2017

ASX Announcement 22 June 2017 ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an

More information

For personal use only

For personal use only Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for

More information

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183) Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

QUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010

QUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010 QUALITAS MEDICAL GROUP LIMITED CORPORATE PRESENTATION January 2010 Contents Our Business Corporate Developments Growth Strategies Financial Highlights Summary Business Overview Who We Are Established in

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017

artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Table of Contents General Information and Business Activities Economic Development of

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Südzucker Group Capital market forum Rhine Neckar

Südzucker Group Capital market forum Rhine Neckar Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development

More information

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( ) Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017 Mental Health November 28, 2017 MYnd Analytics, Inc. OTC MYND We believe MYnd Analytics is commercializing a very valuable predictive technology in a field of medicine, mental disorders, where desicisions

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

1Q2005. Hera Group presentation

1Q2005. Hera Group presentation 1Q2005 Hera Group presentation 1 Y2005 has been characterized by a stream of achievements: Corporate Governance A new BoD was appointed in April. Further penetration of the Hera Gas market: 1,500 new clients

More information

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Designing a Smoke-Free Future

Designing a Smoke-Free Future Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

Jefferies Healthcare Conference. June 2016

Jefferies Healthcare Conference. June 2016 Jefferies Healthcare Conference June 2016 Today s Speakers John Figueroa Chief Executive Officer Vic Breed Chief Financial Officer Joined Genoa in July 2014 Previously served the dual roles of CEO of Apria

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

Operational Efficiency:

Operational Efficiency: Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

1Q 2015 Results A Positive Start to 2015

1Q 2015 Results A Positive Start to 2015 1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results

More information

Cowen Healthcare Conference

Cowen Healthcare Conference Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT

More information

Insurance Guide For Dental Healthcare Professionals

Insurance Guide For Dental Healthcare Professionals Insurance Guide For Dental Healthcare Professionals Dental Benefits Basics What is dental insurance? Unlike traditional insurance, dental benefits are not meant to cover all oral healthcare needs. The

More information

Cochlear Limited 2018 Annual General Meeting Chairman s Address

Cochlear Limited 2018 Annual General Meeting Chairman s Address Cochlear Limited 2018 Annual General Meeting Chairman s Address 16 October 2018 Rick Holliday-Smith Chairman Ladies and gentlemen Cochlear reported a record net profit of $246 million for FY18, an increase

More information

Position Profile Chief Executive Officer Feeding America San Diego San Diego, CA

Position Profile Chief Executive Officer Feeding America San Diego San Diego, CA Position Profile Chief Executive Officer Feeding America San Diego San Diego, CA Feeding America San Diego is seeking an experienced and inspirational Chief Executive Officer to lead this impactful and

More information

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking

More information

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars

More information

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15. [NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS

More information

Telekom Austria Group Results for the First Quarter May 16, 2007

Telekom Austria Group Results for the First Quarter May 16, 2007 Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store Actual Store Low Price & Great Value $5,6, 6.% CAP Rate Open & paying rent--available for immediate sale Lower price point and great value Offered free & clear; loans available today with as little as

More information

WELCOME TO ACTELION S AGM 2015

WELCOME TO ACTELION S AGM 2015 WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre

More information